Leonard Zehr, Author at BioTuesdays

Developments

ContraVir Pharma to merge with Ciclofilin Pharma

ContraVir Pharmaceuticals (NASDAQ:CTRV) has entered into a definitive merger agreement with closely-held Ciclofilin Pharmaceuticals. Under the accord, ContraVir will acquire all of the outstanding equity interests in...

May 31, 2016

Developments

Maxim likes ContraVir merger with Ciclofilin

The merger of ContraVir Pharmaceuticals (NASDAQ:CTRV) with closely-held Ciclofilin Pharmaceuticals strengthens ContraVir’s position in the hepatitis B virus (HBV) space, according to a new report from Maxim Group...

May 31, 2016

Feature

Lipocine advancing pipeline, PDUFA for oral TRT

By Len Zehr With a PDUFA date of June 28 for an FDA decision on its oral testosterone replacement therapy (TRT) product candidate, TLANDO, Lipocine’s (NASDAQ:LPCN) next two pipeline product candidates are advancing...

May 31, 2016

Markets

Roth ups Titan Pharma price target to $10

Roth Capital Partners has raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to $10 from $7.75 after the FDA approved Titan’s six-month Probuphine implant for the treatment of opioid addiction. The stock...

May 30, 2016

Developments

FDA approves Titan’s Probuphine implant for opioid dependence

The FDA has approved Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant, the first product for the long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral...

May 26, 2016

Developments

BioSyent signs distribution pact for two CV products

BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved...

May 25, 2016

Markets

Roth resumes coverage of Fibrocell at buy

Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target...

May 24, 2016

Feature

Delivra implementing U.S. expansion strategy for topical creams

By Len Zehr The major initiative for Delivra (TSX-V:DVA) in 2016 is to introduce its flagship LivRelief topical pain and nerve creams to the U.S. market, initially through a U.S. web store and Amazon, and then through...

May 24, 2016

Developments

Vital enrolls first subject in Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has enrolled the first subject in its Phase 3 trial designated, VTL-308, to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. ELAD is an extracorporeal human...

May 23, 2016

Developments

Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis...

May 23, 2016

Author - Leonard Zehr

ContraVir Pharma to merge with Ciclofilin Pharma

Maxim likes ContraVir merger with Ciclofilin

Lipocine advancing pipeline, PDUFA for oral TRT

Roth ups Titan Pharma price target to $10

FDA approves Titan’s Probuphine implant for opioid dependence

BioSyent signs distribution pact for two CV products

Roth resumes coverage of Fibrocell at buy

Delivra implementing U.S. expansion strategy for topical creams

Vital enrolls first subject in Phase 3 ELAD trial

Roth adjusts DelMar Pharma price target to $12

Subscribe